HLA types in women with cervical human papillomavirus (HPV) lesions prospectively followed up for 10 years

Cytopathology

Volumn 7, Issue 2, 1996, Pages 99-107

  Syrjanen K ^a   Nurmi, T ^a   Mantyjarvi R ^a   Ilonen, J ^b   Syrjanen S ^a,b   Surcel, H M ^c   Yliskoski, M ^a   Vayrynen M ^a   Chang, F ^a   Saarikoski, S ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

cervix; CIN; follow up; HLA; human papillomavirus

Indexed keywords

ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HLA TYPING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 9244261605     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2303.1996.38882388.x     Document Type: Article

References (40)

1. Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973; 288: 704-6.
2. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973; i: 904-7.
3. Festenstein H, Awad J, Hitman GA et al. New HLA DNA polymorphisms associated with autoimmune diseases. Nature 1986; 322: 64-67.
4. Tiwari JL, Terasaki PI, eds. HLA and Disease Associations. Berlin: Springer-Verlag, 1985.
5. Klein J, Juretic A, Baxevanis CN, Nagy ZA. The traditional and a new version of the mouse H-2 complex. Nature 1981; 291: 455-60.
6. Panza N, Del Vecchio L, Maio M, De Felice M, Lombardi G, Minozzi M, Zappacosta S. Strong association between an HLA-DR antigen and thyroid carcinoma. Tissue Antigens 1982; 20: 155-8.
7. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991; 352: 723-5.
8. Heiland Å, Börresen AL, Kaern J, Rönningen KS, Thorsby E. HLA antigens and cervical carcinoma. Nature 1992; 356: 23.
9. Glew S, Dyer PA. HLA antigens and cervical carcinoma. Nature 1992; 356: 22.
10. Klitz W. Viruses, cancer and the MHC. Nature 1992; 356: 17-18.
11. Han R, Breitburd F, Marche PN, Orth G. Linkage of regression and malignant conversion of rabbit viral papillomas to MHC class H genes. Nature 1992; 356: 66-68.
12. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nature Genetics 1994; 6: 157-62.
13. David ALM, Taylor GM, Gokhale D, Aplin JD, Seif MW, Tindall VR. HLA-DQB1 *03 and cervical intraepithelial neoplasia type III. Lancet 1992; 340: 52.
14. Vandenvelde C, De Poor M, Van Beers D. HLA-DQB 1*03 and cervical intraepithelial neoplasia grades I-III. Lancet 1993; 341: 442-3.
15. Glew SS, Duggan-Keen M, Ghosh AK et al. Lack of association of HLA polymorphisms with human papillomavirus-related cervical cancer. Hum Immunol 1993; 37: 157-64.
16. Nawa A, Nishiyama Y, Kobayashi T, Wakahara Y, Okamoto T, Kikkawa F, Tomoda Y. Association of human leukocyte antigen-B1 *03 with cervical cancer in Japanese women aged 35 years and younger. Cancer 1995; 75: 518-21.
17. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184: 9-13.
18. Gissmann L. Linking HPV to cancer. Clin Obstet Gynecol 1989; 32: 141-7.
19. Syrjänen KJ. Papillomaviruses and cancer. In: Syrjänen K, Gissmann L, Koss LG, eds. Papillomaviruses and Human Disease. Berlin: Springer Verlag, 1987: 468-503.
20. Syrjänen K, Parkkinen S, Mäntyjärvi R et al. Human papillomavirus (HPV) type as an important determinant of the natural history of HPV infections in uterine cervix. Eur J Epidemiol 1985; 1: 180-7.
21. Kataja V, Syrjänen K, Syrjänen S et al. Prospective follow-up of genital HPV infections: survival analysis of the HPV typing data. Eur J Epidemiol 1990; 6: 9-14.
22. Kataja V, Syrjänen S, Mäntyjärvi R, Yliskoski M, Saarikoski S, Syrjänen K. Prognostic factors in cervical human papillomavirus (HPV) infections. Sex Transm Dis 1992; 19: 154-60.
23. Mechal WZ, Lo Y-MD, Herrington CS et al. Role of human papillomavirus in determining the HLA associated risk of cervical carcinogenesis. J Clin Pathol 1994; 47: 1077-81.
24. Jenson AB, Kurman RJ, Lancaster WD. Tissue effects of and host response to human papillomavirus infection. Dermatologic Clinics 1991; 9: 203-9.
25. Kirchner H. Immunobiology of human papillomavirus infection. Prog Med Virol 1986; 33: 1-41.
26. Tindle RW, Frazer IH. Immunology of anogenital human papillomavirus (HPV) infection. Aust NZ Obstet Gynaecol 1990; 30: 370.
27. Syrjänen K, Mäntyjärvi R, Parkkinen S, Väyrynen M, Saarikoski S, Syrjänen S, Castren O. Prospective follow-up in assessment of the biological behaviour of cervical HPV-associated dysplastic lesions. In: zur Hausen H, Peto R, eds. Origins of Female Genital Cancer: Virological und Epidemiological Aspects. Banbury Report 21. New York: Cold Spring Harbor Laboratory, 1986: 167-77.
28. Syrjänen K, Mäntyjärvi R, Saarikoski S et al. Factors associated with progression of cervical human papilloma-virus (HPV) infections into carcinoma in situ during a long-term prospective follow-up. Brit J Obstet Gynaecol 1988; 95: 1096-102.
29. Kataja V, Syrjänen K, Mäntyjärvi R et al. Prospective follow-up of cervical HPV infections: Life-table analysis of histopathological, cytological and colposcopic data. Eur J Epidemiol 1989; 5: 1-7.
30. Syrjänen K, Kataja V, Yliskoski M, Chang F, Syrjänen S, Saarikoski S. Natural history of cervical HPV lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 1992; 79: 675-82.
31. Syrjänen K, de Villiers E-M, Väyrynen M, Mäntyjärvi R, Parkkinen S, Castren O. Cervical papillomavirus infection progressing to invasive cancer in less than three years. Lancet 1985; i: 510-1.
32. Reijonen H, Ilonen J, Knip M, Michelsen B, Åkerblom H. HLA-DQ beta-chain restriction fragment length polymorphism as a risk marker in type 1 (insulin-dependent) diabetes mellitus: a Finnish family study. Diabetologia 1990; 33: 357-62.
33. Lonai P, Haran-Ghera N. Genetic resistance to murine leukemia induced by different radiation leukemia virus variants; a comparative study on the role of the H-2 complex. Immunogenetics 1980; 11: 21-29.
34. Fais S, Delle Fratte F, Mancini F, Cioni V, Guadagno M, Vetrano G, Pallone F. Human cervical epithelial cells that express HLA-DR associated with viral infection and activated mononuclear cell infiltrate. J Clin Pathol 1991; 44: 290-2.
35. Falk S, Falk C, Stutte HJ. Lokale Immunreaktionen bei CIN und Zervixkarzinom-Eine histologische und immunohistochemische Studie. Geburtsh u Frauenheilk 1991; 51: 39-44.
36. Tindle RW, Fernando GJP, Sterling JC, Frazer IH. A 'public' T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991; 88: 5887-91.
37. Pfister H, Fuchs PG. Relation of papillomaviruses to anogenital cancer. Dermatologie Clinics 1991; 9: 267-76.
38. Wright TC Jr, Richart RM. Role of human papillomavirus in the pathogenesis of genital tract warts and cancer. Gynecol Oncol 1990; 37: 151-64.
39. Quan MB, Moy RL. The role of human papillomavirus in carcinoma. J Am Acad Dermatol 1991; 25: 698-705.
40. Torres LM, Cabrera T, Concha A, Oliva MR, Ruiz-Cabello F, Garrido F. HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens 1993; 41: 65-71.